Cordis Corporation: The CYPHER® Sirolimus-Eluting Coronary Stent Outperforms the Taxus Stent in Small Coronary Vessels According to New Clinical Data Analysis Published in the Journal of the American College of Cardiology

WARREN, N.J.--(BUSINESS WIRE)--The CYPHER® Sirolimus-eluting Coronary Stent reduced by more than half the rate of major adverse cardiac events (MACE) compared to the Taxus Stent in small coronary vessels according to data appearing this week in the Journal of the American College of Cardiology.
MORE ON THIS TOPIC